Envoy Medical, Inc.
COCHNasdaq
$0.70
↓ -7.7%Jul 17 close · end-of-day
Price
1Y↓ -56.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$48.4M
Enterprise Value
$48.4M
P/E
—
P/S
206.7
P/B
4.8
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$234,000.00
Net Income (TTM)
-$23.1M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-9881.2%
Net Margin
-9875.6%
ROE
-227.4%
ROIC
-179.8%
Debt / Equity
—
Net Cash
—
Return 1Y
-58.7%
Company profile
Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include hearing aids; Esteem middle ear implants; bone conduction devices, such as auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.
- CEO
- Brent T. Lucas
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Headquarters
- Minnesota
- Website
- www.envoymedical.com
Management & directors
- Lucas Brent T.Chief Executive Officer
- Potashnick RobertInterim CFO
Roles derived from SEC Form 4 filings.
Earnings
COCH Q 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$39,000.00↓ -15.2%
Diluted EPS-$0.08↓ -72.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | $237,000.00 | $316,000.00 | $225,000.00 | $241,000.00 |
| Gross profit | — | — | — | — | — |
| Operating income | -$5.2M | -$8.7M | -$18.4M | -$19.3M | -$22.3M |
| Net income | -$251,633.00 | -$15.9M | -$29.9M | -$20.8M | -$23.8M |
| Diluted EPS | — | -$1.57 | -$2.54 | -$1.49 | -$1.23 |
| Operating cash flow | -$3.2M | -$8.8M | -$17.1M | -$17.9M | -$18.2M |
| Free cash flow | — | -$9.0M | -$17.2M | -$18.9M | -$18.4M |
| Gross margin | — | — | — | — | — |
| Operating margin | — | -3673.4% | -5809.8% | -8558.2% | -9240.7% |
| Net margin | — | -6718.6% | -9469.0% | -9242.2% | -9857.3% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $68,000.00 | $56,000.00 | $42,000.00 | $46,000.00 | $78,000.00 | $42,000.00 | $75,000.00 | $39,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$4.9M | -$5.0M | -$4.5M | -$5.1M | -$5.1M | -$5.7M | -$6.4M | -$6.0M |
| Net income | -$3.9M | -$6.0M | -$4.6M | -$5.0M | -$5.7M | -$6.5M | -$6.6M | -$4.4M |
| Diluted EPS | -$0.29 | -$0.39 | -$0.40 | -$0.29 | -$0.32 | -$0.35 | -$0.27 | -$0.08 |
| Operating cash flow | -$4.6M | -$2.6M | -$5.1M | -$3.7M | -$4.5M | -$4.3M | -$5.7M | -$6.1M |
| Free cash flow | — | -$3.8M | — | -$3.7M | -$4.5M | -$4.3M | -$5.9M | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -7135.3% | -8878.6% | -10828.6% | -11102.2% | -6500.0% | -13590.5% | -8513.3% | -15279.5% |
| Net margin | -5804.4% | -10642.9% | -10995.2% | -10865.2% | -7294.9% | -15433.3% | -8781.3% | -11156.4% |
Company news
Jul 14, 2026
- 6d agoEnvoy Medical Reports Positive 12-Month Data Showing Continued Improvement in Speech Perception in Study of First-of-Its-Kind Fully Implanted Cochlear Implantfinance.yahoo.com
- 6d agoEXCLUSIVE: Envoy Medical Builds Momentum With Improved Cochlear Implant Trial Resultsfinance.yahoo.com
- 6d agoAngioDynamics (ANGO) Reports Q4 Loss, Beats Revenue Estimatesfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-29 | Lucas Brent T.· Chief Executive Officer | Award | 32,856 | $0.60 | $19,680.74 | filing |
| 2026-02-12 | TAYLOR GLEN A | Buy | 18,750,000 | $0.40 | $7.5M | filing |
| 2026-02-12 | BRYNELSEN CHARLES | Buy | 1,000,000 | $0.40 | $400,000.00 | filing |
| 2026-02-12 | Patel Mona Chetan | Buy | 312,500 | $0.40 | $125,000.00 | filing |
| 2026-02-12 | Potashnick Robert· Interim CFO | Buy | 212,500 | $0.40 | $85,000.00 | filing |
| 2026-02-12 | Kantor Susan | Buy | 96,150 | $0.40 | $38,460.00 | filing |
| 2026-02-12 | Lucas Brent T.· Chief Executive Officer | Buy | 62,500 | $0.40 | $25,000.00 | filing |
| 2025-11-28 | Lucas Brent T.· Chief Executive Officer | Award | 18,105 | $0.71 | $12,908.87 | filing |
Latest 8 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.